Trials / Completed
CompletedNCT04235959
A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus. The study will also measure how much tirzepatide gets into the bloodstream and how long it takes the body to remove it. The study will last about six or eight months for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2020-10-21
- Primary completion
- 2021-08-17
- Completion
- 2021-08-17
- First posted
- 2020-01-22
- Last updated
- 2023-07-06
- Results posted
- 2023-07-06
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04235959. Inclusion in this directory is not an endorsement.